REQUEST FOR PROPOSAL: DRUG DEVELOPMENT

Funding Agency:
Alzheimer’s Drug Discovery Foundation

The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.

Deadlines for Letters of Intent: Feb. 5, 2024; May 13, 2024; Sep. 30, 2024

Agency Website

Eligibility Requirements

Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
  • Biotechnology companies. Existing companies and new startups are both eligible.
  • NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).

Amount Description

Up to $5,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Clinical Science
Medical - Translational

External Deadline

February 5, 2024